Daily 1 a-OH-D2 in Hormone Refractory Prostate Cancer: Assessment of Clinical and Biochemical Effects
Abstract
Vitamin D and its metabolites via binding to cellular vitamin D receptors principally regulate bone homeostasis, but also have been observed to be potent growth inhibitors of neoplastic cells. Preclinical work has strongly implied vitamin D- based therapy could be effective in prostate cancer. Early clinical work with vitamin D has been complicated by its significant calcemic effects. 1alpha-OH-D2 is a vitamin D analog with less calcemic effects but significant growth inhibitory effects. Objective anti-tumor activity was observed in a prostate cancer patient during an initial phase I study of lalpha-OH-D2. We are performing a phase II study of daily lalpha-OH-D2 in patients with advanced androgen-independent prostate cancer. We have observed transient mild hypercalcemia without symptoms in selected patients. No objective tumor responses have been observed to date and the study is too early to discuss the primary endpoint of time-to- treatment failure. Pilot correlative studies evaluating plasma transforming growth factor Beta1 levels and T cell receptor- associated signal transducing zeta chain expression in peripheral mononuclear cells in patients undergoing study participation are underway without significant preliminary data. Observations to date continue to support the possibility that therapy with daily la-OH-D2 in androgen-independent prostate cancer could be effective.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1999
- Accession Number
- ADA380213
Entities
People
- Howard H. Bailey
Organizations
- University of Wisconsin–Madison